National study finds donor age not a factor in most corneal transplants

(SACRAMENTO, Calif.) — Ten years after a transplant, a cornea from a 71-year-old donor is likely to remain as healthy as a cornea from a donor half that age, and corneas from donors over 71 perform slightly less well but still remain healthy for most transplant recipients, according to a study funded by the National Eye Institute (NEI) and led by the UC Davis Health System Eye Center and the University of Cincinnati Eye Institute.

The results were published online in Ophthalmology on Nov. 15, and presented on the same day in New Orleans at a joint meeting of the Eye Bank Association of America and the Cornea Society.

The Cornea Donor Study found that 10-year success rates remained steady at 75 percent for corneal transplants from donors 34 to 71 years old. It also found slightly higher success rates for donors under 34, and somewhat lower rates for donors over 71.

In the U.S., three-fourths of cornea donors are within the 34 to 71 age range, with one-third of donors at the upper end of the range, from 61 to 70 years old. When the study began in 2000, many surgeons would not accept corneas from donors over 65.

"The findings clearly demonstrate that most corneal transplants have remarkable longevity regardless of donor age," said Mark Mannis, chair of ophthalmology and vision sciences, director of UC Davis Health System's Eye Center and co-chair of the study. "The majority of patients continued to do well after 10 years, even those who received corneas from the oldest donors."

The Corneal Donor Study "supports continued expansion of the corneal donor pool beyond age 65," said study co-chair Edward J. Holland, professor of ophthalmology at the University of Cincinnati and director of the Cornea Service at the Cincinnati Eye Institute.

A corneal transplant is performed when decreased vision or discomfort from corneal damage cannot be corrected with lenses or medication. It involves removing a portion of the damaged cornea and grafting corneal tissue from a deceased donor in its place. More than 46,000 corneal transplants were performed in the United States last year. In addition, U.S. eye banks exported about 20,000 corneas to other countries in 2012, an increase of 7 percent over 2011.

The supply of corneas does not meet the demand internationally, and as the aging population grows at home and abroad, the need for corneal transplants is expected to grow, too. The Cornea Donor Study was designed to address whether making use of donor corneas across the full range of ages available might help solve this problem," said Maryann Redford, a clinical research program director at NEI.

The study (see NCT00006411 at http://clinicaltrials.gov) compared graft survival rates for corneas from two donor age groups, aged 12 to 65 and aged 66 to 75. Coordinated by the Jaeb Center for Health Research in Tampa, Fla., it involved 80 clinical sites across the U.S. and enrolled 1,090 people aged 40 to 80 who were eligible for transplants. Forty-three eye banks provided donor corneas, which met the quality standards of the Eye Bank Association of America. Patients received the corneas without respect to patient age using a transplant procedure called penetrating keratoplasty, in which the central part of the damaged cornea is removed, and a full-thickness donor cornea is sutured in its place.

About two thirds of patients had an inherited corneal disease called Fuchs' dystrophy, and one third had corneal swelling after cataract surgery. These conditions involve loss of cells in the innermost (endothelial) layer of the cornea and are leading reasons for corneal transplants reported to U.S. eye banks. Graft failure was defined as the need for a new transplant, or a cloudy cornea that caused blurred vision for at least three months.

The investigators originally planned to follow patients for five years post-transplant. In 2008, they reported that the five-year success rate was identical — 86 percent — for transplants from donors aged 12 to 65 and those aged 66 to 75. However, when the investigators examined endothelial cells in the transplanted corneas, they found that older corneas had a slightly higher rate of cell loss. Higher cell loss at six months also predicted a higher likelihood of graft failure at five years. That prompted an expansion of the study to determine if donor age would affect transplant viability 10 years after the procedure.

During the follow up, 663 participants remained eligible and willing to continue with the study. The investigators report that at 10 years, the transplant success rates for corneas from donors aged 12 to 65 and aged 66 to 75 remained similar, at 77 percent and 71 percent, respectively. However, when the investigators separated the donors into smaller age groups, they found some differences. The success rate remained steady at 75 percent for the vast majority of donors ages 34 to 71. But it increased to 96 percent for donors age 12 to 33 and decreased to 62 percent for donors age 72 to 75.

The investigators also re-evaluated the endothelial cells lining the inner cornea in a subgroup of 176 patients who had a successful transplant at 10 years and for whom high-quality images of the cells were available. The data confirmed the trend in cell loss seen at five years. At 10 years, corneas from donors over age 65 had a slightly higher rate of endothelial cell loss (79 percent) compared to those from donors age 65 and under (76 percent). The youngest corneas, from donors age 12 to 33, had the highest number of cells before surgery and the lowest rate of cell loss at 10 years (67 percent).

"The cell loss data parallels the graft survival data, but we don't yet know if a given number of cells at five years is predictive of graft failure at 10 years," said Jonathan Lass, professor of ophthalmology at Case Western Reserve University and University Hospitals Case Medical Center in Cleveland and medical director of the study's cornea image analysis reading center. That analysis is being done and will be released at a later date, he said.

The investigators note that corneal surgeries have changed in the past decade. Penetrating keratoplasty was the standard procedure used for corneal transplants when the study was launched. But today, most patients with Fuchs' dystrophy or corneal swelling undergo endothelial keratoplasty, which involves replacing only the endothelial layer rather than the entire central cornea. The ongoing Cornea Preservation Time Study (NCT01537393), led by Lass and also funded by NEI, is examining the factors contributing to transplant success after endothelial keratoplasty. In the meantime, the investigators say the current study provides the most comprehensive data on the relationship between donor age and corneal transplant outcome.

Given the high success rate for transplants involving young donors (under age 34), the investigators wrote that their analysis "raises the question…of whether age-matching of donors and recipients is appropriate at the extremes of recipient age." Such age-matching is already a frequent practice for children and other young patients in need of corneal transplants, who routinely get corneas from young donors. But young donor corneas are relatively rare. In 2012, corneal donors under age 31 comprised less than 10 percent of the U.S. donor pool.

Surgeons often seek the youngest corneal tissue available regardless of patient age. Historically, some surgeons set extremely restrictive upper age limits, even refusing tissue from donors over age 50, Mannis said.

"The study demonstrates the viability of older donor tissue in the majority of cases with endothelial disease," he said. "In time, we hope the study will have a lasting impact on the practice of corneal transplant surgery. Although the results suggest that age-matching may be appropriate for the very youngest donors and patients, we do not think it is necessary in the vast majority of cases."

The Cornea Donor Study was funded through cooperative agreements EY012728 and EY012358 from NEI. Additional support was provided by the Eye Bank Association of America, Bausch & Lomb, Tissue Banks International, Vision Share, San Diego Eye Bank, The Cornea Society, Katena Products, ViroMed Laboratories, Midwest Eye-Banks (Michigan Eye-Bank, Illinois Eye-Bank, Cleveland Eye Bank, and Lions Eye Bank of New Jersey), Konan Medical Corp., Eye Bank for Sight Restoration, SightLife, Sight Society of Northeastern New York (Lions Eye Bank of Albany), and Lions Eye Bank of Oregon.

NEI leads the federal government's research on the visual system and eye diseases. NEI supports basic and clinical science programs that result in the development of sight-saving treatments. For more information, visit http://www.nei.nih.gov.

UC Davis Health System improves health and health care, around the corner and across the globe. Diverse in expertise but united in purpose, UC Davis faculty, staff and students collaborate daily to solve urgent real-world problems, translate research into new cures and eliminate health disparities. Whether treating complex injuries, improving cancer care or explaining autism, UC Davis Health System's unique combination of academic excellence and social responsibility advances health for all. For more information, visit http://healthsystem.ucdavis.edu.